Key statistics
On Monday, Gain Therapeutics Inc (GANX:NMQ) closed at 1.55, 74.16% above the 52 week low of 0.89 set on Aug 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.47 |
---|---|
High | 1.78 |
Low | 1.45 |
Bid | 1.54 |
Offer | 1.55 |
Previous close | 1.43 |
Average volume | 204.86k |
---|---|
Shares outstanding | 25.54m |
Free float | 24.23m |
P/E (TTM) | -- |
Market cap | 36.52m USD |
EPS (TTM) | -1.33 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
- Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
- Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
- Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
- Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
- Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
- Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
- Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
- Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
- Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
More ▼